IAN MORTIMER - 24 May 2023 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
PRESIDENT & CEO, Director
Signature
/s/ Cassandra Robinson, Attorney-in-fact
Issuer symbol
XENE
Transactions as of
24 May 2023
Net transactions value
-$1,163,499
Form type
4
Filing time
26 May 2023, 19:10:49 UTC
Previous filing
14 Mar 2023
Next filing
12 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XENE Common Shares Options Exercise $402,068 +42,592 +710% $9.44* 48,592 24 May 2023 Direct F1
transaction XENE Common Shares Tax liability $305,850 -7,310 -15% $41.84 41,282 24 May 2023 Direct F2
transaction XENE Common Shares Sale $707,339 -17,069 -41% $41.44 24,213 24 May 2023 Direct F3
transaction XENE Common Shares Options Exercise $202,674 +20,576 +85% $9.85* 44,789 24 May 2023 Direct F4
transaction XENE Common Shares Tax liability $163,260 -3,902 -8.7% $41.84 40,887 24 May 2023 Direct F2
transaction XENE Common Shares Sale $545,215 -13,179 -32% $41.37 27,708 24 May 2023 Direct F5
transaction XENE Common Shares Options Exercise $60,794 +6,172 +22% $9.85* 33,880 24 May 2023 Direct F4
transaction XENE Common Shares Tax liability $48,995 -1,171 -3.5% $41.84 32,709 24 May 2023 Direct F2
transaction XENE Common Shares Sale $58,376 -1,407 -4.3% $41.49 31,302 24 May 2023 Direct F6
holding XENE Common Shares 14,300 24 May 2023 By Spouse.

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -42,592 -100% $0.000000* 0 24 May 2023 Common Shares 42,592 $9.44 Direct F1, F7
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -20,576 -100% $0.000000* 0 24 May 2023 Common Shares 20,576 $9.85 Direct F4, F7
transaction XENE Stock Option (Right to Buy) Options Exercise $0 -6,172 -100% $0.000000* 0 24 May 2023 Common Shares 6,172 $9.85 Direct F4, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The exercise price was converted from $9.76 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
F2 Represents the closing price of the Company's common shares on May 23, 2023 for purposes of net settlement calculations.
F3 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.29 to $41.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4 The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the Reverse Stock Split. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
F5 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.26 to $41.47, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F6 The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.48 to $41.52, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F7 The shares subject to the option are fully vested and exercisable.